BioLineRx Ltd - Asset Resilience Ratio

Latest as of December 2025: 43.09%

BioLineRx Ltd (BLRX) has an Asset Resilience Ratio of 43.09% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$17.63 Million

Cash + Short-term Investments

Total Assets

$40.90 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2008–2025)

This chart shows how BioLineRx Ltd's Asset Resilience Ratio has changed over time. Check BioLineRx Ltd (BLRX) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down BioLineRx Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BLRX market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$17.63 Million	43.09%
Total Liquid Assets	$17.63 Million	43.09%

Asset Resilience Insights

Very High Liquidity: BioLineRx Ltd maintains exceptional liquid asset reserves at 43.09% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

BioLineRx Ltd Industry Peers by Asset Resilience Ratio

Compare BioLineRx Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
ALTEOGEN Inc KQ:196170	Biotechnology	55.57%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	34.94%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Inventiva S.A PA:IVA	Biotechnology	52.73%

Annual Asset Resilience Ratio for BioLineRx Ltd (2008–2025)

The table below shows the annual Asset Resilience Ratio data for BioLineRx Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	43.09%	$17.63 Million	$40.90 Million	+19.63pp
2024-12-31	23.46%	$9.13 Million	$38.91 Million	-37.14pp
2023-12-31	60.60%	$38.74 Million	$63.92 Million	+7.59pp
2022-12-31	53.02%	$40.49 Million	$76.38 Million	-1.22pp
2021-12-31	54.24%	$44.15 Million	$81.39 Million	+42.07pp
2020-12-31	12.17%	$5.76 Million	$47.29 Million	-29.26pp
2019-12-31	41.43%	$22.19 Million	$53.57 Million	-6.14pp
2018-12-31	47.56%	$26.75 Million	$56.23 Million	-25.22pp
2017-12-31	72.78%	$44.37 Million	$60.97 Million	-12.36pp
2016-12-31	85.14%	$33.15 Million	$38.94 Million	+3.04pp
2015-12-31	82.10%	$42.12 Million	$51.30 Million	+2.32pp
2014-12-31	79.78%	$28.85 Million	$36.17 Million	+33.22pp
2013-12-31	46.56%	$9.29 Million	$19.95 Million	+33.94pp
2012-12-31	12.62%	$3.07 Million	$24.31 Million	-46.29pp
2011-12-31	58.91%	$17.28 Million	$29.34 Million	+40.78pp
2010-12-31	18.13%	$7.92 Million	$43.66 Million	-8.56pp
2008-12-31	26.69%	$8.18 Million	$30.64 Million	--

pp = percentage points

About BioLineRx Ltd

NASDAQ:BLRX USA Biotechnology

Market Cap

$12.27 Million

Market Cap Rank

#26483 Global

#5450 in USA

Share Price

$2.82

Change (1 day)

+4.44%

52-Week Range

$2.18 - $4.44

All Time High

$24.30